Assembly Biosciences reported fourth-quarter results that substantially beat Wall Street expectations. The company posted a GAAP loss per share of $0.55, which was $3.01 better than analyst estimates. Revenue reached $72.3 million, surpassing forecasts by $35.02 million.
The biotech company's strong performance represents a significant outperformance against market expectations. Assembly Biosciences focuses on developing innovative medicines for patients with severe diseases, particularly in hepatitis B and other liver conditions.